Saturday, July 25, 2026 | 06:50 PM ISTहिंदी में पढें
Business Standard
Notification Icon
userprofile IconSearch

Page 2 - Cadila Healthcare

Q2 preview: Non-Covid revenues to hint at normalisation for healthcare cos

Companies may, however, report sequential drop in numbers as Q1FY22 coincided with outbreak of second Covid wave, say brokerages

Q2 preview: Non-Covid revenues to hint at normalisation for healthcare cos
Updated On : 17 Oct 2021 | 10:55 PM IST

Cadila gets DCGI nod to conduct phase III trials for two-dose Covid vaccine

Shares of Cadila Healthcare Ltd were trading at Rs 563.95 per scrip on BSE, up 0.29 percent from their previous close.

Cadila gets DCGI nod to conduct phase III trials for two-dose Covid vaccine
Updated On : 05 Oct 2021 | 4:53 PM IST

Shilpa Medicare to make drug substance for Cadila's ZyCoV-D vaccine

ZyCoV-D is the world's first approved DNA vaccine, and the first Covid-19 vaccine in India to be approved for use in adolescents 12 years and above

Shilpa Medicare to make drug substance for Cadila's ZyCoV-D vaccine
Updated On : 25 Sep 2021 | 12:51 AM IST

India to target children for Covid-19 vaccine from October: Report

Zydus Cadila's Covid vaccine ZyCoV-D will be given

India to target children for Covid-19 vaccine from October: Report
Updated On : 22 Sep 2021 | 11:13 AM IST

Stocks to watch: SBI Card, Adani Ports, Cadila Healthcare, HCL Tech, AU SFB

IT company AGC Networks on Monday said its board has approved the appointment of Essar Group's Anshuman Ruia as executive director of the company

Stocks to watch: SBI Card, Adani Ports, Cadila Healthcare, HCL Tech, AU SFB
Updated On : 21 Sep 2021 | 8:43 AM IST

Zydus to sell two brands to PE firm True North's portfolio company

Both drugs, Mifegest Cytolog are used for medical termination of pregnancy

Zydus to sell two brands to PE firm True North's portfolio company
Updated On : 20 Sep 2021 | 6:40 PM IST

Cadila jumps nearly 8% after Covid-19 vaccine gets India emergency use nod

Shares of Cadila Healthcare Ltd jumped 7.9% on Monday after India last week approved the drugmaker's Covid-19 vaccine for emergency use in adults and children aged 12 years and above

Cadila jumps nearly 8% after Covid-19 vaccine gets India emergency use nod
Updated On : 23 Aug 2021 | 11:33 AM IST

Back to old normal: Pharma industry returns to pre-pandemic growth level

In this first instalment of a four-part series on how some of the defining numbers in key sectors are springing back to the pre-pandemic level, Sohini Das looks at India's pharmaceutical sector

Back to old normal: Pharma industry returns to pre-pandemic growth level
Updated On : 29 Jul 2021 | 4:10 PM IST

Cadila arm completes sale of animal health business for Rs 2,921 crore

Cadila Healthcare on Thursday said its wholly-owned subsidiary Zydus Animal Health and Investment has completed sale of its animal healthcare established markets

Cadila arm completes sale of animal health business for Rs 2,921 crore
Updated On : 15 Jul 2021 | 11:43 AM IST

Two stock ideas by Vaishali Parekh: Buy CESC, Cadila Healthcare

Cadila Healthcare's stock has taken base near Rs 600 levels on two occasions recently, forming a good support zone

Two stock ideas by Vaishali Parekh: Buy CESC, Cadila Healthcare
Updated On : 12 Jul 2021 | 8:05 AM IST

Cadila Healthcare arm recalls 21,240 bottles of diabetes drug in US

Viona Pharmaceuticals Inc is recalling over 21,000 bottles of metformin hydrochloride extended-release tablets manufactured by Ahemdabad-based Cadila Healthcare

Cadila Healthcare arm recalls 21,240 bottles of diabetes drug in US
Updated On : 04 Jul 2021 | 1:27 PM IST

Cadila, Bayer to extend JV partnership for three years: Statement

Cadila Healthcare and Bayer (South East Asia) have decided to extend the operations of their joint venture by three years with effect from June

Cadila, Bayer to extend JV partnership for three years: Statement
Updated On : 21 Jun 2021 | 2:58 PM IST

Zydus Cadila seeks regulator nod for clinical trials on Covid-19 therapy

Company says product helps treating mild coronavirus patients and reduces hospitalisation.

Zydus Cadila seeks regulator nod for clinical trials on Covid-19 therapy
Updated On : 27 May 2021 | 10:13 AM IST

Zydus Cadila to sell India animal health business for Rs 2,921 crore

We are sure that ZAHL will continue to grow and strengthen its position, said Pankaj Patel

Zydus Cadila to sell India animal health business for Rs 2,921 crore
Updated On : 13 May 2021 | 1:51 AM IST

Multiples Alternate Asset Mgt-led group to buy Cadila's animal health biz

The deal is to sell one of Cadila's two businesses on a slump sale basis as a going concern, for a lump sum of Rs 2,921 cr on cash-free and debt-free basis

Multiples Alternate Asset Mgt-led group to buy Cadila's animal health biz
Updated On : 12 May 2021 | 2:09 PM IST

Cadila Healthcare's Hepatitis C drug gets approval for emergency use

Approval from the drug regulator follows late-stage study of the medicine

Cadila Healthcare's Hepatitis C drug gets approval for emergency use
Updated On : 23 Apr 2021 | 10:56 PM IST

Cadila Healthcare testing two-shot regimen for ZyCoV-D, data likely by May

The company is conducting phase 3 efficacy trials on a three-dose regimen of its DNA plasmid technology-based Covid-19 vaccine, which is in its last leg

Cadila Healthcare testing two-shot regimen for ZyCoV-D, data likely by May
Updated On : 22 Apr 2021 | 12:06 AM IST

Pharma shares in demand; Cipla, Laurus Labs, Dr Lal Pathlabs hit new highs

Analysts at Phillip Capital believe that it is not over for the Indian pharma - and that it is all set for a sectoral value upgrade

Pharma shares in demand; Cipla, Laurus Labs, Dr Lal Pathlabs hit new highs
Updated On : 12 Apr 2021 | 11:02 AM IST

Nifty outlook and stock picks by Sameet Chavan: Buy BPCL, sell Axis Bank

Price-wise, BPCL's stock seems to have a sturdy structure on the weekly time frame and, looking at the lower degree chart, the recent price correction appears to have completed

Nifty outlook and stock picks by Sameet Chavan: Buy BPCL, sell Axis Bank
Updated On : 22 Mar 2021 | 8:35 AM IST

Here is a derivative strategy for Cadila Health by Vinay Rajani of HDFC Sec

The stock price of Cadila Healthcare has broken out from the consolidation which held for last three weeks

Here is a derivative strategy for Cadila Health by Vinay Rajani of HDFC Sec
Updated On : 15 Jan 2021 | 7:22 AM IST